What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Armando Santoro mainly focuses on Internal medicine, Surgery, Oncology, Gastroenterology and Chemotherapy.
His works in Sorafenib, Phases of clinical research, Clinical trial, Hazard ratio and Carcinoma are all subjects of inquiry into Internal medicine.
Surgery and Adverse effect are commonly linked in his work.
His studies in Oncology integrate themes in fields like Cancer, Colorectal cancer, Metastasis and Immunology.
His Gastroenterology study integrates concerns from other disciplines, such as Incidence, Neutropenia, Pleural disease, Vinorelbine and Lymphoma.
His Chemotherapy research is multidisciplinary, incorporating elements of Nausea, Radiation therapy and Toxicity.
His most cited work include:
- Sorafenib in Advanced Hepatocellular Carcinoma (7596 citations)
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (4248 citations)
- Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer (1165 citations)
What are the main themes of his work throughout his whole career to date?
Armando Santoro mainly investigates Internal medicine, Oncology, Surgery, Chemotherapy and Gastroenterology.
He integrates many fields, such as Internal medicine and In patient, in his works.
His Oncology research includes themes of Hepatocellular carcinoma, Breast cancer, Clinical trial and Colorectal cancer.
His Surgery study often links to related topics such as Adverse effect.
The concepts of his Chemotherapy study are interwoven with issues in Toxicity, Disease and Sarcoma.
Armando Santoro combines subjects such as Neutropenia, Refractory and Lymphoma with his study of Gastroenterology.
He most often published in these fields:
- Internal medicine (65.34%)
- Oncology (44.00%)
- Surgery (24.93%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (65.34%)
- Oncology (44.00%)
- Transplantation (10.29%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Oncology, Transplantation, In patient and Chemotherapy.
His Internal medicine study frequently draws connections to other fields, such as Gastroenterology.
His biological study spans a wide range of topics, including Breast cancer, Clinical trial, Disease and Brentuximab vedotin.
Armando Santoro has included themes like Cyclophosphamide, Stem cell, Cumulative incidence and Hazard ratio in his Transplantation study.
He specializes in Chemotherapy, namely Phases of clinical research.
Armando Santoro works mostly in the field of Refractory, limiting it down to topics relating to Copanlisib and, in certain cases, Follicular lymphoma.
Between 2017 and 2021, his most popular works were:
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. (258 citations)
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (182 citations)
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study (160 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Armando Santoro focuses on Internal medicine, Oncology, Nivolumab, Gastroenterology and Chemotherapy.
His work in Hepatocellular carcinoma, Hazard ratio, Phases of clinical research, Neutropenia and Adverse effect are all subfields of Internal medicine research.
His research integrates issues of Cabozantinib, Checkmate and Carcinoma in his study of Hepatocellular carcinoma.
His Oncology research is multidisciplinary, relying on both Brentuximab vedotin and Refractory.
His Nivolumab research is multidisciplinary, incorporating elements of Ipilimumab, Lymphoma and Clinical trial.
The subject of his Chemotherapy research is within the realm of Surgery.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
